13F Holdings
中文EN

IMCC IM Cannabis Corp. IFRS

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1792030 · Reporting currency CAD · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY1.3%
TTM net income YoY-6.9%
TTM EPS YoY—
Revenue 3-yr CAGR0.2%
Net income 3-yr CAGR—

Margins

Gross margin17.7%
Operating margin-21.2%
Net margin-20.7%
FCF margin8.6%
EBITDA margin—

Returns

ROE-1,496.2%
ROA-31.9%
ROIC (approx.)-63.6%
Asset turnover1.54x

Leverage & solvency

Liabilities / assets111.4%
Debt / equity—
Current ratio0.67x
Interest coverage-3.31x

Cash quality & payout

Operating cash flow / net income-0.42x
Accruals ratio-45.2%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue54.73M54.03M48.80M54.34M34.05M
Cost of revenue45.05M45.58M37.97M43.04M25.46M
Gross profit9.69M8.45M9.85M9.16M6.33M
SG&A expense9.52M8.02M11.01M21.46M17.22M
Operating income-11.59M-10.23M-12.79M-30.79M-23.04M
Interest expense3.50M4.77M3.67M1.97M673,000
Pretax income-11.66M-12.79M-9.46M-26.06M-164,000
Income tax92,000-1.02M771,000-1.14M500,000
Net income-11.32M-10.59M-9.50M-188.89M-17.76M
EBITDA———-27.98M-20.91M
EPS (basic)—-4.51-4.45-157.83-3.06
EPS (diluted)—-4.51-4.45-161.88-6.70
Weighted avg. shares (diluted)——12.82M7.49M5.98M
Balance sheet
Cash & equivalents2.73M863,0001.81M2.45M13.90M
Short-term investments————3.13M
Receivables4.32M5.42M4.83M3.32M14.48M
Inventory4.27M3.21M9.98M16.59M29.39M
Current assets22.74M23.36M24.27M32.67M81.18M
PP&E, netmay include right-of-use assets (IFRS)3.71M3.73M5.06M5.22M30.27M
Goodwill1.89M6.68M10.10M9.77M121.30M
Intangibles1.22M3.33M5.80M7.91M30.89M
Total assets31.74M39.19M48.81M60.68M287.39M
Current liabilities34.01M34.92M32.85M33.82M51.23M
Short-term debt14.33M15.14M12.12M9.25M9.50M
Long-term debt936,000466,000394,000399,000392,000
Total debt15.27M15.61M12.51M9.64M9.89M
Total liabilities35.35M36.04M35.11M36.88M82.44M
Shareholders' equity-3.73M5.24M14.47M22.65M201.24M
Net debt12.54M14.75M10.70M7.20M-4.01M
Shares outstanding5.89M3.09M2.23M1.26M1.14M
Cash flow statement
Operating cash flow4.72M-1.08M-8.07M-12.64M-34.37M
Capital expenditure13,000156,000581,0001.56M4.58M
Free cash flow4.70M-1.23M-8.66M-14.20M-38.95M
Investing cash flow-531,000-470,000-1.18M-1.53M-9.01M
Financing cash flow1.15M3.83M9.42M4.76M48.73M
Depreciation & amortization———2.81M2.12M
Stock-based compensation14,000369,000225,0003.77M7.47M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.